Login to Your Account

Gate-pass 'rindo'? Data from GBM phase II clears path to FDA, says Celldex

By Randy Osborne
Staff Writer

Saturday, November 15, 2014

With encouraging interim phase II data in hand and a large phase III trial under way, Celldex Therapeutics Inc. is making plans to talk with regulators about the chances for approval of rindopepimut (rindo), an immunotherapy vaccine targeting epidermal growth factor variant III in GBM.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription